SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Charles C. Wykoff, MD, PhD, discusses data from the GALE long-term extension study investigating Apellis Pharmaceuticals’ Syfovre for geographic atrophy.
At 36 months of continuous pegcetacoplan dosing, Syfovre (pegcetacoplan injection) reduced GA lesion growth by up to 35% when dosed monthly and by approximately 24% when dosed every other month. In addition, patients with foveal sparing at baseline saw up to 42% growth reduction when treated monthly, Wykoff said.
Wykoff also discussed the study’s safety